Skip to main content

Table 1 Demographic, basal clinical and laboratory parameters

From: Safety and efficacy of direct-acting antiviral drugs in the treatment of chronic hepatitis C virus infection in patients with thalassemia: a prospective study

Variables No (%) or median (IQR)
Male gender 44 (50%)
Age (years) 29 (12–36)
Subjects with comorbidities 28 (31.82%)
 Hypertension 8 (13.63%)
 Osteoporosis 12 (13.63%)
 HBV 4 (4.54%)
 Drug users 4 (4.54%)
Splenectomy 88 (100%)
Iron chelation agent  
 Deferiprone 28 (31.82)
 Deferasirox 60 (68.18)
Hemoglobin (g/dl) 8.25 (7.3–9)
Platelet count (×109/L) 543 (430–632)
WBCs (× 109/L) 27.3 (18.3–50)
AST (IU/L) 71.50 (47–82.30)
ALT (IU/L) 54.45 (28–74)
S. bilirubin (mg/dl) 2.9 (2.5–4)
Direct bilirubin (mg/dl) 0.6 (0.5–0.98)
Albumin (g/dl) 4 (3.8–4.8)
INR 1.2 (1.1–1.3)
S. creatinine (mg/dl) 0.65 (0.6–0.8)
Ferritin (ng/mL) 2500 (1800–4000)
PCR HCV RNA (IU/ml) 941757 (187771–1400000)
FIB-4 score 0.52 (0.47–0.73)